(Reuters) -Eli Lilly and Co posted a 41.5% rise in quarterly profit on Friday, helped by demand for its diabetes and cancer drugs, and as it benefited from the U.S. government’s move to stock up on the drugmaker’s COVID-19 antibody drug for emergency use.
The company’s COVID-19 therapy belongs to a class of drugs known as monoclonal antibodies and has been authorized for use in the United States in patients who are at risk of serious illness from the infection.
The company reported worldwide revenue of $871.2 million in the fourth quarter from the therapy, bamlanivimab.
Net earnings rose to $2.12 billion, or $2.32 per share, in the fourth quarter ended Dec. 31 from $1.50 billion, or $1.64 per share, a year earlier.
Overall sales rose 21.7% to $ 7.44 billion.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment